ContraVir Pharmaceuticals (CTRV) Sees Large Volume Increase
Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) saw strong trading volume on Thursday . 1,826,495 shares traded hands during trading, an increase of 417% from the previous session’s volume of 353,165 shares.The stock last traded at $0.28 and had previously closed at $0.23.
Several equities research analysts recently commented on the company. ValuEngine cut ContraVir Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Maxim Group cut ContraVir Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th.
A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Barclays PLC raised its holdings in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 229.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 179,480 shares of the biopharmaceutical company’s stock after buying an additional 124,958 shares during the quarter. Barclays PLC owned about 1.08% of ContraVir Pharmaceuticals worth $50,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 4.48% of the company’s stock.
ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.
See Also: S&P 500 Index
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.